Does Semaglutide Cause Muscle Loss? What Body-Composition Studies Show

Quick Answer

Weight loss with semaglutide can include a reduction in lean body mass. However, lean mass measured by DXA is not the same as skeletal muscle, and current evidence does not establish that semaglutide directly causes disproportionate muscle wasting. In the STEP 1 body-composition analysis, total fat mass decreased by 19.3%, while total lean body mass decreased by 9.7%. Because fat mass fell more, lean mass increased as a proportion of total body weight.

Substantial weight loss rarely comes entirely from body fat. Whether it results from dietary changes, bariatric surgery, medication, or a combination of approaches, some reduction in lean tissue can occur.

This has led to questions about <strong>semaglutide muscle loss</strong>, including searches for “Ozempic muscle loss” and “Wegovy muscle loss.” The key issue is not simply how much weight people lose, but what proportion comes from fat mass, lean tissue, water, or skeletal muscle.

Semaglutide reduces appetite and calorie intake as part of how semaglutide works. The U.S. Wegovy prescribing information states that semaglutide lowers body weight with a greater loss of fat mass than lean mass. However, interpreting the available body-composition evidence requires understanding what the studies actually measured.

What STEP 1 Found About Semaglutide and Lean Mass

The most frequently cited evidence comes from an exploratory body-composition analysis of the STEP 1 trial.

The analysis included 140 participants who underwent dual-energy X-ray absorptiometry, or DXA:

The analysis reported the following changes in the semaglutide group:

Body weight decreased by 3.6% in the placebo group, with no major body-composition changes reported.

These findings show two things at the same time:

Therefore, it would be misleading to say either that semaglutide caused no lean-mass loss or that the study proved severe skeletal-muscle wasting.

For the broader STEP results and expected weight changes, see semaglutide for weight loss.

Lean Mass Is Not the Same as Muscle Mass

This distinction is essential when interpreting semaglutide lean-mass data.

DXA divides the body into measurements that include fat mass, lean soft tissue, and bone mineral content. Its lean-mass estimate includes much more than skeletal muscle, such as:

DXA does not directly isolate or measure every skeletal muscle in the body. Changes in hydration and glycogen can also influence lean-mass estimates.

Consequently, a 9.7% reduction in DXA-measured lean body mass should not be described as a 9.7% loss of muscle. The STEP 1 analysis did not determine how much of that change represented skeletal muscle, water, organ tissue, or other fat-free components.

Muscle health also involves more than tissue quantity. Strength, walking speed, balance, and the ability to perform daily activities can be clinically important even when a scan shows less lean mass.

What Other Semaglutide Body-Composition Studies Found

STEP 1 is important, but it is not the only relevant study.

SUSTAIN 8: Semaglutide 1.0 mg in Type 2 Diabetes

A DXA substudy of SUSTAIN 8 evaluated semaglutide 1.0 mg and canagliflozin in adults with type 2 diabetes.

After 52 weeks, the semaglutide group had:

The body-composition differences between semaglutide and canagliflozin were not statistically significant. Because the study did not include a placebo group, the investigators cautioned that the specific independent effect of either medication on body composition remained uncertain.

SEMALEAN: Lean Mass and Muscle Function

The prospective SEMALEAN study followed adults with obesity receiving semaglutide 2.4 mg for 12 months.

Among the 106 participants who completed the study:

These findings suggest that a reduction in measured lean mass does not automatically mean that muscle function will deteriorate. However, SEMALEAN was an uncontrolled prospective study, so it cannot prove that semaglutide improved strength or preserved muscle independently of other factors.

Does Semaglutide Cause More Lean-Mass Loss Than Dieting?

The available evidence does not answer this question cleanly.

A frequently cited rule of thumb suggests that approximately one-quarter of weight lost during conventional dieting may come from fat-free mass. In practice, the proportion varies considerably according to:

The STEP 1 body-composition substudy did not compare semaglutide with a diet-only group that achieved the same amount of weight loss. Its placebo group lost much less weight, making an equal-weight-loss comparison impossible.

Comparing percentages from unrelated diet, bariatric-surgery, and medication studies can also be misleading because the participants, interventions, and measurement methods differ.

The most accurate conclusion is that semaglutide-associated weight loss includes some loss of lean mass, while fat loss predominates. Current human evidence remains insufficient to determine whether semaglutide has a direct muscle-wasting effect separate from the effects of substantial weight loss and reduced energy intake.

Does Ozempic or Wegovy Cause Muscle Loss?

Ozempic and Wegovy both contain semaglutide, but the available evidence should not be applied to the brands interchangeably without qualification.

The STEP 1 body-composition analysis studied once-weekly injectable semaglutide 2.4 mg—the dose associated with the Wegovy weight-management regimen. It did not specifically study every Ozempic dose, formulation, or patient population.

SUSTAIN 8 used semaglutide 1.0 mg in adults with type 2 diabetes, but it compared the medication with canagliflozin rather than placebo.

Therefore, searches for <strong>Ozempic muscle loss</strong> and <strong>Wegovy muscle loss</strong> lead to related evidence, but the expected body-composition change may differ according to dose, treatment indication, starting body composition, total weight loss, nutrition, activity, age, and health status.

How to Support Muscle During Semaglutide Treatment

No strategy can guarantee that all lean mass will be retained during substantial weight loss. The following measures may help support muscle health.

1. Include Resistance Exercise

Muscle-strengthening exercise provides a stimulus for maintaining strength and skeletal muscle.

General U.S. physical-activity guidance recommends muscle-strengthening activities involving the major muscle groups on at least two days per week. The appropriate type and intensity depend on current fitness, mobility, medical conditions, and injury risk.

People who are inactive, frail, or managing cardiovascular, orthopedic, or other health conditions should ask a qualified professional how to begin safely.

2. Set an Individualized Protein Target

A 2025 joint advisory from four U.S. nutrition and obesity organizations notes that protein targets of 1.2–1.6 g/kg per day have been proposed during active weight loss. However, it also emphasizes uncertainty over whether calculations for people with obesity should use actual weight, adjusted or ideal weight, or fat-free mass.

An alternative target of 80–120 grams per day has also been proposed, but this is not appropriate for every person.

Protein needs should be individualized according to body size, age, dietary pattern, activity, treatment stage, and kidney function. A clinician or registered dietitian can help establish an appropriate target instead of relying on a universal formula.

3. Avoid Nutritionally Inadequate Intake

Strong appetite suppression, nausea, vomiting, or early fullness can make it difficult to consume enough protein, fluids, and micronutrients.

Contact your healthcare provider if side effects prevent you from eating or drinking adequately. Persistent vomiting, dehydration, or worsening weakness should not be treated as a normal or necessary part of weight loss. See the guide to common semaglutide side effects for additional warning signs.

4. Monitor Function as Well as Weight

Scale weight cannot show whether a change came from fat, water, or lean tissue. Consider tracking functional measures such as:

DXA or professionally supervised body-composition testing may be useful for selected higher-risk patients, but routine scans are not necessary for everyone. Consumer body-composition scales can also vary with hydration and should not be treated as precise measurements of muscle.

Individual semaglutide patient experiences may provide context about appetite, energy, and treatment tolerability, but personal reviews cannot establish whether someone has lost fat or skeletal muscle.

Who May Need Closer Monitoring?

Closer nutritional and functional monitoring may be particularly important for:

Unexpected weakness can have causes other than muscle loss. A healthcare provider may need to evaluate calorie and protein intake, hydration, medication effects, blood glucose, anemia, thyroid function, or other potential contributors.

The Bottom Line

Semaglutide-associated weight loss can include a measurable reduction in lean body mass. In the STEP 1 DXA analysis, however, fat mass decreased approximately twice as much in relative terms as lean mass, and the lean-to-fat mass ratio improved.

The study did not prove that all measured lean-mass loss was skeletal muscle or that semaglutide directly causes muscle atrophy. Newer studies also show that muscle strength can remain stable or improve even when lean mass decreases, although the evidence is still limited.

Maintaining adequate nutrition, including an individualized protein target, combining treatment with resistance exercise, and monitoring strength and physical function can help make the focus broader than the number on the scale.

Sources